| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000039472 |
| Receipt No. | R000045009 |
| Scientific Title | Research on the effects of long-term intake of yogurt together with ground sesame on eye and nasal discomfort due to allergic rhinitis and allergic conjunctivitis. |
| Date of disclosure of the study information | 2020/02/13 |
| Last modified on | 2020/09/23 (Ver. 4) |
| Basic information | ||
| Public title | Research on the effects of long-term intake of yogurt together with ground sesame on eye and nasal discomfort due to allergic rhinitis and allergic conjunctivitis. | |
| Acronym | Research on the effects of long-term intake of yogurt together with ground sesame on eye and nasal discomfort due to allergic rhinitis and allergic conjunctivitis. | |
| Scientific Title | Research on the effects of long-term intake of yogurt together with ground sesame on eye and nasal discomfort due to allergic rhinitis and allergic conjunctivitis. | |
| Scientific Title:Acronym | Research on the effects of long-term intake of yogurt together with ground sesame on eye and nasal discomfort due to allergic rhinitis and allergic conjunctivitis. | |
| Region |
|
|
| Condition | ||
| Condition | Healthy Adults | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Evaluate the effects of yogurt together with ground sesame or yogurt for intake 4 weeks on eye and nasal discomfort. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | QOL score
Specific IgE (36 items) at the beginning of Interventional and after 4weeks of Interventional. |
| Key secondary outcomes | Th1/Th2 rate
Intestinal Flora Physical examination(body height, weight, BMI, lean body mass) at the beginning of Interventional and after 4weeks of Interventional |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Single blind -investigator(s) and assessor(s) are blinded |
| Control | No treatment |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 3 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Intake 200g of yogurt together with 2 tablespoons of ground sesame for 4 weeks. | |
| Interventions/Control_2 | Intake 200g of yogurt for 4 weeks. | |
| Interventions/Control_3 | none | |
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1.Persons who received a sufficient explanation of the purpose and contents of the study, have the capacity to consent, applied with free will with sufficient understanding, and agreed to participate with a written document
2.Male and Female who are 30 years old or more and under 60 years old 3.Persons who have troubles of eye and nasal discomfort. 4.Persons who can come to the designated day and be inspected. |
|||
| Key exclusion criteria | 1.Persons who have any disease and are judged to have necessary treatment by the principal investigator.
2.Persons who are taken or applied medications for the treatment in the last one month. (excluding medicine used for needed basis such as headache, menstrual cramps and colds, etc.) 3.Persons with medical history with visceral disease and blood disease. 4.Persons who are judged to have diseases by the principal investigator and result of blood test or self-report. 5.Persons with self-report of medical history within last 6 months. 6.Persons who have severe anemia. 7.Persons who have an addiction to alcohol or a mental disease. 8.Persons who are a smoker or has been smoking for within last 10 years. 9.Persons who may cause allergic symptoms to test foods. 10.Persons who received hormone replacement therapy in the past 6 months. 11.Persons who were hospitalized and received treatment in the past 6 months. 12.Persons whose life style will change during the study period. 13.Persons who plan to intake new health functional foods and supplement foods during the study period. 14.Persons who participates in other clinical studies or participated in the last 3 months or plan to participate in other clinical studies. 15.Persons who are pregnant, planning or hoping to be pregnant during the study period, currently lactating. 16.Persons who were judged as inappropriate for subjects by the principal investigator. |
|||
| Target sample size | 45 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Akasaka Family Clinic | ||||||
| Division name | Clinic Director | ||||||
| Zip code | 107-0052 | ||||||
| Address | Akasaka Plaza bldg. 3F, 2-15-15 Akasaka, Minato-ku, Tokyo, JAPAN | ||||||
| TEL | 03-5562-8825 | ||||||
| moltofelice2005@yahoo.co.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Healthcare Systems Co., Ltd. | ||||||
| Division name | Research and Development Department | ||||||
| Zip code | 105-0004 | ||||||
| Address | Nisshin Tatemono Shinbashi Bld. 7F, 4-6-15 Shinbashi, Minato-ku, Tokyo, JAPAN | ||||||
| TEL | 03-6809-2722 | ||||||
| Homepage URL | |||||||
| watanabe@hc-sys.jp | |||||||
| Sponsor | |
| Institute | Akasaka Family Clinic |
| Institute | |
| Department | |
| Funding Source | |
| Organization | gram3 inc. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | The Ethics Committee of Healthcare Systems Co., Ltd. |
| Address | Nisshin Tatemono Shinbashi Bld. 7F, 4-6-15 Shinbashi, Minato-ku, Tokyo, JAPAN |
| Tel | 03-6809-2722 |
| kakehashi@hc-sys.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | 43 |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045009 |